Abstract:Introduction: Autologous mononuclear cells (MNCs) have been used in vascular regenerative therapy since the identification of endothelial progenitor cells (EPCs). However, the efficacy of autologous EPC therapy for diseases such as diabetes and connective tissue disorders is limited due to deficiencies in the number and function of EPCs. To address this, we developed a novel RE-01 cells that enriches pro-angiogenic cells from peripheral blood MNCs (PBMNCs). Methods: PBMNCs were collected from healthy volunteers following ethical guidelines. RE-01 cells were cultured in the presence of specific growth factors for 5 days without media change. Flow cytometry was used to analyze cell surface markers. Tube formation assays, EPC culture assays, and mRNA analysis were performed to evaluate angiogenic potential. The efficacy of RE-01 cells upon transplantation into ischemic hind limbs of mice was evaluated. Results: RE-01 cells exhibited a significant increase in pro-angiogenic cells such as M2 macrophages and angiogenic T cells, in contrast to PBMNCs, while the number of inflammatory cells reduced. In vitro assays demonstrated the enhanced angiogenic abilities of RE-01 cells, supported by increased mRNA expression of angiogenesis-related cytokines. In vivo studies using mouse ischemic hind limb models have shown that blood flow and angiogenesis improved following RE-01 cell transplantation. Transplantations for 3 consecutive days significantly improved the number of pericyte-recruited vessels in the severely ischemic hind limbs of mice. Conclusions: RE-01 cells showed promising results in enhancing angiogenesis and arteriogenesis, possibly owing to the presence of M2 macrophages and angiogenic T cells. These cells also demonstrated anti-fibrotic effects. The efficacy of RE-01 cells has been confirmed in mouse models, suggesting their potential for treating ischemic vascular diseases. Clinical trials are planned to validate the safety and efficacy of RE-01 cell therapy in patients with connective tissue disease and unhealed ulcers. We hope that this new RE-01 cell therapy will prevent many patients from undergoing amputation.

Cell-based interventions for therapeutic angiogenesis: review of potential cell sources.

Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

Statin and Stromal Cell-Derived Factor-1 Additively Promote Angiogenesis

Cell-modified Bioprinted Microspheres for Vascular Regeneration

Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia

Therapeutic neovascularization for ischemic heart disease

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Cell Transplantation Regional Angiogenesis for Ischemic Myocardium

Therapeutic Angiogenesis and Tissue Revascularization in Ischemic Vascular Disease

Vascular Growth in Ischemic Limbs: A Review of Mechanisms and Possible Therapeutic Stimulation

Regulators of angiogenesis and strategies for their therapeutic manipulation

Bioengineering Cell Therapy for Treatment of Peripheral Artery Disease

The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia

Sourcing of human peripheral blood-derived myeloid angiogenic cells under xeno-free conditions for the treatment of critical limb ischemia

Adipose-Derived Stem Cells to Treat Ischemic Diseases: The Case of Peripheral Artery Disease

State of the field: cellular and exosomal therapeutic approaches in vascular regeneration

Cell therapy for cardiovascular disease: a comparison of methods of delivery

Novel cell therapy with ex vivo cultured peripheral blood mononuclear cells significantly impacts angiogenesis in the murine ischemic limb model

Endothelial progenitor cells: precursors for angiogenesis

Therapeutic Angiogenesis and Cardiovascular Disease: A Review

Therapeutic neovascularization for coronary disease: current state and future prospects